Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treatment for recurrent hepatitis C.

R M Ghobrial1

  • 1Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA.

Minerva Chirurgica
|November 7, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transplantation for Hepatocellular Carcinoma: Is There a Tumor Size Limit?

Transplantation proceedings·2018
Same author

Treatment of Refractory Gastrointestinal Bleeding in Patients With Portal Hypertension: A Case Series and Treatment Algorithm.

Transplantation proceedings·2017
Same author

Graft-Infiltrating Macrophages Adopt an M2 Phenotype and Are Inhibited by Purinergic Receptor P2X7 Antagonist in Chronic Rejection.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
Same author

Liver transplantation in an adult with adenomatosis and congenital absence of the portal vein: a case report.

Transplantation proceedings·2014
Same author

Incidence and severity of acute cellular rejection in recipients undergoing adult living donor or deceased donor liver transplantation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2009
Same author

Recipient morbidity after living and deceased donor liver transplantation: findings from the A2ALL Retrospective Cohort Study.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2008
Same journal

Unexpected evolution of COVID-19 in a heart transplant patient with multimorbidity recently submitted to thoracic surgery.

Minerva chirurgica·2020
Same journal

Ongoing clinical trials on axillary management.

Minerva chirurgica·2020
Same journal

Axillary management after neoadjuvant treatment.

Minerva chirurgica·2020
Same journal

Axillary observation alone versus sentinel node biopsy: past, present and future perspectives.

Minerva chirurgica·2020
Same journal

Patient flow for the management of ostomy patients.

Minerva chirurgica·2020
Same journal

The management of "fragile" and suspected COVID-19 surgical patients during pandemic: an Italian single-center experience.

Minerva chirurgica·2020
See all related articles

Hepatitis C virus (HCV) recurrence after liver transplant (OLT) is common. New antiviral strategies are needed to prevent allograft failure and improve outcomes for patients undergoing OLT for HCV.

Area of Science:

  • Hepatology
  • Transplantation Medicine
  • Virology

Background:

  • Hepatitis C virus (HCV) is the leading indication for orthotopic liver transplantation (OLT) globally.
  • While OLT for HCV offers good survival, HCV recurrence in the allograft is nearly universal within the first year.
  • Recurrent HCV can lead to graft failure in the short-term and destruction long-term.

Purpose of the Study:

  • To review current medical and surgical therapeutic options for recurrent HCV post-OLT.
  • To identify patient populations most susceptible to recurrent HCV or most likely to benefit from antiviral treatment.
  • To discuss the role and outcomes of re-transplantation (re-OLT) for graft failure due to recurrent HCV.

Main Methods:

  • Literature review of existing studies on recurrent HCV after OLT.

Related Experiment Videos

  • Analysis of current antiviral therapies and their efficacy and adverse events.
  • Evaluation of outcomes for re-OLT in selected patients.

    • Main Results:

    • HCV recurrence post-OLT is a significant clinical challenge.
    • Current antiviral therapies have limitations in efficacy and tolerability.
    • Retransplantation (re-OLT) is a viable option for selected patients with graft failure.

    Conclusions:

    • There is a critical need for effective antiviral regimens to treat or prevent HCV recurrence after OLT.
    • Identifying high-risk patient groups is crucial for targeted antiviral intervention.
    • Careful selection and timely re-OLT can yield positive results in specific cases.